Home・Aktien・Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

4.13 -3.5

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.12

Max

4.28

Schlüsselkennzahlen
By Trading Economics
Einkommen	11M 51M
Verkäufe	6.5M 113M
KGV Branchendurchschnitt	5.45 57.371
EPS	0.31
Gewinnspanne	45.374
Angestellte	100
EBITDA	6.2M 81M

Dividenden
By Acuity
Nächstes Ergebnis	9. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-7.1M 720M
Vorheriger Eröffnungskurs	7.63
Vorheriger Schlusskurs	4.13

Nachrichtenstimmung

By Acuity

32%

68%

104 / 340 Ranking in Healthcare

Ironwood Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 21:51 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

20. Aug. 2026, 20:06 UTC

Ironwood Pharmaceuticals Inc shares are lower during Thursday's session, reversing earlier gains amid rising crude oil prices and increasing U.S. Treasury yields.

19. Aug. 2026, 19:46 UTC

Ironwood Pharmaceuticals shares are higher, supported by declining bond yields and broader market trends. The stock is trading near the upper end of its one-month range.

18. Aug. 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today amid cautious market sentiment influenced by rising treasury yields and inflation concerns.

17. Aug. 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, maintaining its position near the upper end of its one-month range amid rising Treasury yields and inflation concerns.

14. Aug. 2026, 23:01 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, following a drop in U.S. retail sales that raised concerns about consumer spending and economic health.

13. Aug. 2026, 23:36 UTC

Ironwood Pharmaceuticals Inc shares are lower during after-market hours, with no specific news identified to explain the decline. Trading activity remains routine.

12. Aug. 2026, 19:21 UTC

Ironwood Pharmaceuticals is higher Wednesday, buoyed by overall strength in U.S. stocks, despite a recent pullback earlier in the session.

11. Aug. 2026, 22:06 UTC

Ironwood Pharmaceuticals Inc shares are higher in after-market trading, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

10. Aug. 2026, 19:36 UTC

Ironwood Pharmaceuticals Inc shares are lower today, with no specific news identified. The stock remains significantly down since Friday's close amid broader market volatility.

7. Aug. 2026, 19:46 UTC

Ironwood Pharmaceuticals Inc shares are higher during Friday's session, maintaining a position above the 20-day moving average, despite earlier fluctuations.

6. Aug. 2026, 23:06 UTC

Ironwood Pharmaceuticals shares are higher in after-market hours, reflecting positive movement since Thursday's close. No specific news was identified to explain the price action.

5. Aug. 2026, 23:02 UTC

Ironwood Pharmaceuticals shares are higher in after-market trading, continuing a notable increase since Wednesday's close, despite no specific news identified.

4. Aug. 2026, 23:01 UTC

Ironwood Pharmaceuticals Inc. shares are lower in after-market trading, showing routine volatility while remaining above the 20-day moving average. No specific news was identified.

3. Aug. 2026, 19:26 UTC

Ironwood Pharmaceuticals is trading higher today, continuing a rally since Friday's close, amid broader market gains and falling energy prices.

31. Juli 2026, 23:26 UTC

Ironwood Pharmaceuticals Inc shares are trading higher in after-market hours, maintaining upward momentum since Friday's close. No specific news was identified for this movement.

30. Juli 2026, 20:51 UTC

Ironwood Pharmaceuticals shares declined in after-market trading, despite broader market gains. The stock remains below its 20-day moving average and near a one-month low.

29. Juli 2026, 20:04 UTC

Ironwood Pharmaceuticals Inc shares are trading lower amid broader market dynamics, including rising oil prices due to escalating Middle East tensions.

27. Juli 2026, 20:06 UTC

Ironwood Pharmaceuticals shares are higher today, reflecting broader market dynamics, despite earlier declines and a significant drop in oil prices.

24. Juli 2026, 23:26 UTC

Ironwood Pharmaceuticals shares gained modestly in after-market trading, following a volatile session amid broader turmoil in the bond market.

20. Juli 2026, 18:36 UTC

Ironwood Pharmaceuticals Inc is trading higher, reaching a session peak before settling within its one-month range. No specific news was identified for today's movement.

Peer-Vergleich

Kursveränderung

Ironwood Pharmaceuticals Inc Prognose

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Ironwood Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

104 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.